These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8078637)

  • 1. Combined use of 123I-labelled BCD-F9 and 4C4 monoclonal antibody with dissimilar specificity for breast cancer: implication for the detection limit of immunolymphoscintigraphy in the assessment of axillary lymph node metastases.
    Schatten C; Barrada M; Mandeville R; Enzelsberger H; Angelberger P; Czerwenka K; Kubista E; Pateisky N
    Nucl Med Commun; 1994 Jun; 15(6):422-9. PubMed ID: 8078637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoscintigraphy with 131I-labelled HMFG2 and HMFG1 F(ab')2 in the pre-operative detection of clinical and subclinical lymph node metastases in breast cancer patients.
    Athanassiou A; Pectasides D; Pateniotis K; Tzimis L; Natsis P; Lafi A; Arapantoni P; Koutsiouba P; Taylor-Papadimitriou J; Epenetos A
    Int J Cancer Suppl; 1988; 3():89-95. PubMed ID: 3209306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Initial results of immunolymphoscintigraphy in the diagnosis of axillary lymph node involvement in breast cancer patients].
    Pateisky N; Philipp K; Kubista E; Skodler WD; Burchell J
    Geburtshilfe Frauenheilkd; 1986 Oct; 46(10):681-4. PubMed ID: 3803863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunolymphoscintigraphy for the detection of lymph node metastases from breast cancer.
    Tjandra JJ; Russell IS; Collins JP; Andrews JT; Lichtenstein M; Binns D; McKenzie IF
    Cancer Res; 1989 Mar; 49(6):1600-8. PubMed ID: 2647290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunolymphoscintigraphy in breast cancer: evaluation using 131I-labeled monoclonal antibody B72.3.
    Fig LM; Brown RS; von Moll L; Appelman HD; Stevens R; Harness J; August D; Sondak VK; Chang AE; Zasadny KR; Fisher SJ; Johnson JW; Wicha MS; Colcher D; Lichter AS; Wahl RL
    Nucl Med Biol; 1998 Apr; 25(3):251-60. PubMed ID: 9620631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunolymphoscintigraphy. A new procedure for noninvasive lymph node staging illustrated by the example of breast cancer].
    Pateisky N; Schatten C; Enzelsberger H; Czerwenka K; Burchell J; Mandeville R
    Dtsch Med Wochenschr; 1988 Feb; 113(7):250-5. PubMed ID: 3342737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
    J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The detection of axillary lymph node metastases from breast cancer by radiolabelled monoclonal antibodies: a prospective study.
    Tjandra JJ; Sacks NP; Thompson CH; Leyden MJ; Stacker SA; Lichtenstein M; Russell IS; Collins JP; Andrews JT; Pietersz GA
    Br J Cancer; 1989 Feb; 59(2):296-302. PubMed ID: 2930695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subareolar injection of technetium-99m nanocolloid yields reliable data on the axillary lymph node tumour status in breast cancer patients with previous manipulations on the primary tumour: a prospective study of 117 patients.
    Maza S; Thomas A; Winzer KJ; Hüttner C; Blohmer JU; Hauschild M; Richter M; Krössin T; Geworski L; Zander A; Guski H; Munz DL
    Eur J Nucl Med Mol Imaging; 2004 May; 31(5):671-5. PubMed ID: 14745517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunodetection of lymph node invasion in prostatic cancer. The use of iodine 123 (123I)-labeled monoclonal anti-prostatic acid phosphatase (PAP) 227 A F(ab')2 antibody fragments in vivo.
    Leroy M; Teillac P; Rain JD; Saccavini JC; Le Duc A; Najean Y
    Cancer; 1989 Jul; 64(1):1-5. PubMed ID: 2731106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunolymphscintigraphy of axillary lymph node metastases in breast cancer patients using monoclonal antibodies: first clinical findings.
    Mandeville R; Pateisky N; Philipp K; Kubista E; Dumas F; Grouix B
    Anticancer Res; 1986; 6(6):1257-63. PubMed ID: 3813482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel lymph node mapping in early-stage breast cancer: technical issues and results with vital blue dye mapping and radioguided surgery.
    Canavese G; Gipponi M; Catturich A; Di Somma C; Vecchio C; Rosato F; Percivale P; Moresco L; Nicolò G; Spina B; Villa G; Bianchi P; Badellino F
    J Surg Oncol; 2000 May; 74(1):61-8. PubMed ID: 10861612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Axillary node removal in clinical node-negative breast carcinoma. Can its indication be individualized by "sentinel node" detection?].
    Reuhl T; Kaisers H; Markwardt J; Haensch W; Hohenberger P; Schlag PM
    Dtsch Med Wochenschr; 1998 May; 123(19):583-7. PubMed ID: 9618639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High resolution sonographic detection of axillary lymph node metastases in breast cancer.
    Yang WT; Ahuja A; Tang A; Suen M; King W; Metreweli C
    J Ultrasound Med; 1996 Mar; 15(3):241-6. PubMed ID: 8919506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET for axillary lymph node staging in primary breast cancer.
    Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.
    Donker M; Straver ME; Wesseling J; Loo CE; Schot M; Drukker CA; van Tinteren H; Sonke GS; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg; 2015 Feb; 261(2):378-82. PubMed ID: 24743607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
    Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
    J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoscintigraphy for detection of lymph node metastases from breast cancer.
    Thompson CH; Lichtenstein M; Stacker SA; Leyden MJ; Salehi N; Andrews JT; McKenzie IF
    Lancet; 1984 Dec; 2(8414):1245-7. PubMed ID: 6150280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes.
    Veronesi U; Paganelli G; Galimberti V; Viale G; Zurrida S; Bedoni M; Costa A; de Cicco C; Geraghty JG; Luini A; Sacchini V; Veronesi P
    Lancet; 1997 Jun; 349(9069):1864-7. PubMed ID: 9217757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer.
    Ahn JH; Son EJ; Kim JA; Youk JH; Kim EK; Kwak JY; Ryu YH; Jeong J
    Acta Radiol; 2010 Oct; 51(8):859-65. PubMed ID: 20670083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.